# Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

> **NCT04452461** · PHASE2 · RECRUITING · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** mFOLFIRINOX
- **DRUG:** Gemcitabine / Nab-paclitaxel

## Key facts

- **NCT ID:** NCT04452461
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2025-12-12
- **Final completion:** 2026-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04452461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04452461, "Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04452461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*